Tu1865 VEDOLIZUMAB TREATMENT PERSISTENCE AND SAFETY IN AN EXTENDED ACCESS PROGRAM (XAP)

Editorial: vedolizumab in inflammatory bowel diseases—less is more? Authors’ reply

“…Townsend and Subramanian 1 in our report of 2‐year results from the vedolizumab extended access programme. Our study showed high patient persistence on vedolizumab every 8 weeks (Q8W) in the first 2 years after reduction in dosing frequency from every 4 weeks (Q4W), with low rates of re‐escalation to Q4W dosing and relapse, and a safety profile consistent with previous reports 2 …”

Editorial: vedolizumab in inflammatory bowel diseases—less is more?

“…Optimal strategies to de‐escalate vedolizumab maintenance therapy for patients with inflammatory bowel disease (IBD) in stable clinical remission have not been adequately investigated. Danese et al reported treatment persistence and safety results among 311 IBD patients enrolled in the vedolizumab extended access program who had their dosing interval changed from 4‐ to 8‐weekly 1 …”